Key result
AI-enabled ECG identifies low LVEF and is linked to ~4.1-fold higher risk of future dysfunction.
Why the study?
Asymptomatic left ventricular dysfunction is treatable and linked to reduced longevity, yet an inexpensive, noninvasive clinical screening tool was unavailable. This study evaluated whether applying artificial intelligence to a routine 12-lead ECG could identify asymptomatic left ventricular dysfunction.
Does application of artificial intelligence to a standard 12-lead ECG accurately identify left ventricular dysfunction (LVEF ≤35%) and predict future ventricular dysfunction?
Cohort (n=97,829)
No
Does application of artificial intelligence to a standard 12-lead ECG accurately identify left ventricular dysfunction (LVEF ≤35%) and predict future ventricular dysfunction?
Applying a convolutional neural network to a routine, low-cost 12-lead ECG provides a powerful screening tool to detect asymptomatic left ventricular dysfunction (EF ≤35%) and identify individuals at high risk for developing it in the future.
Answers are grounded in this paper and cite their sources.
AI-ECG may enable office-based ALVD screening; hypothesis-generating and requires prospective validation before adoption.
Asymptomatic left ventricular dysfunction (ALVD) is present in 3-6% of the general population, is associated with reduced quality of life and longevity, and is treatable when found1-4. An inexpensive, noninvasive screening tool for ALVD in the doctor's office is not available. We tested the hypothesis that application of artificial intelligence (AI) to the electrocardiogram (ECG), a routine method of measuring the heart's electrical activity, could identify ALVD. Using paired 12-lead ECG and echocardiogram data, including the left ventricular ejection fraction (a measure of contractile function), from 44,959 patients at the Mayo Clinic, we trained a convolutional neural network to identify patients with ventricular dysfunction, defined as ejection fraction ≤35%, using the ECG data alone. When tested on an independent set of 52,870 patients, the network model yielded values for the area under the curve, sensitivity, specificity, and accuracy of 0.93, 86.3%, 85.7%, and 85.7%, respectively. In patients without ventricular dysfunction, those with a positive AI screen were at 4 times the risk (hazard ratio, 4.1; 95% confidence interval, 3.3 to 5.0) of developing future ventricular dysfunction compared with those with a negative screen. Application of AI to the ECG-a ubiquitous, low-cost test-permits the ECG to serve as a powerful screening tool in asymptomatic individuals to identify ALVD.
No takes yet. Share an insight, caveat, or question.
Attia et al. (2018) conducted a cohort in Asymptomatic left ventricular dysfunction (ejection fraction ≤35%) (n=97,829). AI-enabled 12-lead ECG convolutional neural network vs. Echocardiogram-determined LVEF (and negative AI screen for prognostic comparison) was evaluated on Identification of left ventricular dysfunction (LVEF ≤35%) and risk of developing future ventricular dysfunction (HR 4.1, 95% CI 3.3-5.0). AI-enabled ECG identified LVEF ≤35% with AUC 0.93 (sensitivity 86.3%, specificity 85.7%) and predicted future dysfunction (HR 4.1; 95% CI 3.3-5.0).
Synapse has enriched 10 related papers. Consider them for comparative context: